Assertion Contradicted AI assessment confidence: 95% certainty 5/5 debate potential 2/5

Rando: The FDA will not approve drugs to treat healthy individuals

Dr. Thomas Rando · a16z Podcast | The Science Of Extending Life · Jan 2, 2019 · at 18:52

Dr. Thomas Rando, director of the Glenn Center for the Biology of Aging at Stanford, discusses regulatory constraints facing longevity medicine on The a16z Podcast.

0:00 / 0:05exact quote · 5.5s

▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark

“There's no way right now that any drug is going to be approved for treatment of healthy people.”

quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →

The claim, plainly

Dr. Thomas Rando asserts that under current FDA regulations, no drug can be approved solely for preventative treatment in healthy individuals.

a quote alone can be ambiguous, so this restates it with the references and context of the conversation around it resolved. AI-written; the tape below the player is the source.

Assessment

The claim states that under FDA regulations as of April 2017, no drug could be approved solely for preventative treatment in healthy individuals. Per the resolution criteria, FDA regulatory records are evaluated to check whether any drug or preventative therapeutic was approved for healthy individuals prior to April 2017. FDA history demonstrates numerous such approvals prior to 2017, including Truvada for HIV Pre-Exposure Prophylaxis (PrEP) in healthy uninfected adults (2012), antimalarial chemoprophylaxis for healthy travelers (e.g., Malarone, Mefloquine), oral contraceptives (1960), and Crestor (rosuvastatin) for primary prevention of cardiovascular events in asymptomatic individuals (2010). Although Dr. Rando was speaking in the context of geroscience (where biological aging itself lacks a recognized disease classification), strict evaluation against the resolution criteria confirms that the FDA had already approved drugs for preventative treatment in healthy individuals.

In July 2012, the FDA approved Truvada (emtricitabine/tenofovir disoproxil fumarate) for pre-exposure prophylaxis (PrEP) to prevent HIV-1 in healthy, uninfected individuals.
In February 2010, the FDA approved rosuvastatin (Crestor) for primary prevention of cardiovascular events in asymptomatic, healthy individuals meeting biomarker risk criteria.
Historical FDA approvals exist for preventative therapeutics in healthy populations, including antimalarial prophylaxis and oral contraceptives.

Checked against

[1] a16z.com [2] a16z.com [3] ny.gov [4] gilead.com [5] nationalacademies.org [6] fda.gov [7] biomedpharmajournal.org [8] seattle.gov

"FDA" "malaria prophylaxis" approval date healthy travelers Thomas Rando a16z podcast 2017 FDA preventative treatment healthy individuals Truvada PrEP FDA approval date 2012 healthy individuals FDA regulations approval preventative drug healthy individuals aging "FDA approved" "preventative" OR "preventive" "healthy individuals" OR "healthy adults" FDA approved drug preventative treatment healthy individuals before April 2017

assessed as of 2026-07-28

This assessment is an AI reading of a public statement, made against the cited references with the confidence shown. It can be wrong. The quote, the tape and the references are all on this page; if something is off, use report an error below. full disclaimer →

Mentioned

FDA healthy people

⚑ Spot an error? Report it

More from Dr. Thomas Rando

Assertion Supported

Rando: Infusing young blood into old animals reverses some aging phenotypes

“What we really know these days is that it does seem that if you infuse Components of a blood from a young animal into an old animal. It actually can revert some of the aging phenotypes from an old state to a younger state, which is something quite different be…”

Dr. Thomas Rando Jan 2, 2019 ▶ 7:24 a16z Podcast | The Science Of Extending Life

Assertion Partly supported

Rando: Young plasma clinical trial underway for early-onset Alzheimer's patients

“The company based on the kind of this work of the blood transfusions is currently conducting a trial of delivering Plasma from young individuals to patients with early onset Alzheimer's disease.”

Dr. Thomas Rando Jan 2, 2019 ▶ 22:58 a16z Podcast | The Science Of Extending Life

Insight

Rando: Science focuses on extending health span, not just life span

“There's a big discrepancy between the notion of life extension and the notion of health span extension.”

Dr. Thomas Rando Jan 2, 2019 ▶ 0:56 a16z Podcast | The Science Of Extending Life

Prediction Not checkable as stated

Rando: Biological age biomarkers will enormously accelerate longevity research

“And I think, you know, the idea of having biomarkers is going to accelerate this field enormously.”

Dr. Thomas Rando Jan 2, 2019 ▶ 6:13 a16z Podcast | The Science Of Extending Life

Rando: The FDA will not approve drugs to treat healthy individuals

More from Dr. Thomas Rando

Turn any episode into a week of clips.